E76 Stock Overview
NeoDynamics AB (publ), a medical technology company, engages in the development of biopsy system to enhance diagnostics and treatment of breast cancer patients.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
NeoDynamics AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.074 |
52 Week High | kr4.00 |
52 Week Low | kr0.07 |
Beta | 1.22 |
1 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -98.99% |
Recent News & Updates
Recent updates
Shareholder Returns
E76 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 0% | -0.5% | 2.0% |
1Y | n/a | -6.1% | 5.9% |
Return vs Industry: Insufficient data to determine how E76 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how E76 performed against the German Market.
Price Volatility
E76 volatility | |
---|---|
E76 Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 4.6% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E76 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine E76's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 9 | Matilda Salen | www.neodynamics.com |
NeoDynamics AB (publ), a medical technology company, engages in the development of biopsy system to enhance diagnostics and treatment of breast cancer patients. It develops NeoNavia, a precision biopsy system that offers clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. The company was incorporated in 2015 and is based in Lidingö, Sweden.
NeoDynamics AB (publ) Fundamentals Summary
E76 fundamental statistics | |
---|---|
Market cap | €2.79m |
Earnings (TTM) | -€7.47m |
Revenue (TTM) | €79.65k |
35.1x
P/S Ratio-0.4x
P/E RatioIs E76 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
E76 income statement (TTM) | |
---|---|
Revenue | kr930.00k |
Cost of Revenue | kr1.50m |
Gross Profit | -kr568.00k |
Other Expenses | kr86.62m |
Earnings | -kr87.19m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
Earnings per share (EPS) | -2.67 |
Gross Margin | -61.08% |
Net Profit Margin | -9,374.95% |
Debt/Equity Ratio | 0% |
How did E76 perform over the long term?
See historical performance and comparison